This study aimed to develop and validate an integrated clinical-radiomics model to predict overall survival (OS) and evaluate the risk of disease progression in patients with isocitrate dehydrogenase-wildtype GBM (IDH-wildtype GBM). The gene discussed is IDH3A; the disease is glioblastoma.